Skip to main content

fenfluramine

Generic: FENFLURAMINE HYDROCHLORIDE·Brand: FINTEPLA, Fintepla

fenfluramine: 4 clinical trials tracked.

fenfluramine evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about fenfluramine, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Clinical Trial Registry Records (4)

Using Fenfluramine to Test the Serotonin Deficiency Theory of Depression

NCT07651293Registry updated 2026-06-16·N/A
Not yet recruiting

Primary endpoint: Change in cortical [11C]Cimbi-36 non-displaceable binding potential (BPND) after dl-fenfluramine versus placebo (serotonin release capacity)

InterventionalRandomizeddouble46 targetStarted 2026-07Completion 2028-121 site · United KingdomImperial College Healthcare NHS Trust

Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome

NCT06118255Registry updated 2026-02-18·Phase 3
Active, not recruiting

Primary endpoint: Change from Baseline in QT interval corrected by Fridericia (QTcF) at Visit 13 (End of Treatment/Early Termination (EOT/ET))

Interventionalopen25 targetStarted 2024-05Completion 2026-1212 sites · Belgium, Germany, Italy, United Kingdom…UCB BIOSCIENCES, Inc.

Fenfluramine for the Treatment of Refractory Epilepsy in Adult Dravet Patients

NCT05560282Registry updated 2026-05-05·Phase 3
Terminated

Primary endpoint: Seizure reduction

Interventionalopen7 targetStarted 2023-01Completion 2025-051 site · CanadaUniversity Health Network, Toronto

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Examine The Efficacy And Safety Of ZX008 In Subjects With CDKL5 Deficiency Disorder Followed By An Open-Label Extension

NCT05064878Registry updated 2026-04-29·Phase 3·ZGNX
Active, not recruiting

Primary endpoint: Percentage Change from Baseline in Countable Motor Seizure Frequency (CMSF) (Part 1)

InterventionalRandomizedquadruple87 targetStarted 2022-03Completion 2027-1146 sites · Austria, Belgium, Georgia, Germany…Zogenix, Inc.